Thus we considered that necroptosis in cluster 1 acted as a tumor suppressor in DLBCL relying on inducing enhanced activation and infiltration of the immune component for improved prognosis, and analysis of APM and CD8+ T cell effector indicated that cluster 1 may be responsive to anti-PD-1/PDL-1 therapy. This evidence concerns the gene CD274 and neoplasm.